PubMed · 2017 · 23 citations · 28 references
MedicineOncologyPathologyCellular MetabolismMolecular OncologyNeoplasiaCancer BiomarkersCancer Molecular PathologyEsophageal CancerMalignant NeoplasmsSquamous Cell CarcinomaTricarboxylic Acid CyclePrognostic BiomarkersPrognostic Marker AssessmentPrognostic Marker EvaluationQuantitative Polymerase Chain ReactionRate-limiting EnzymesSquamous Cell Carcinoma PathologyTricarboxylic Acid Cycle MetabolismTumor Metabolism
<0.05). These results demonstrated that IDH2 was upregulated in ESCC and could be used as a valuable prognostic marker for ESCC patients.
28
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text
Wei Xu, Hui Yang, Ying Liu et al. · Cancer Cell · 2011 · 2.8K citations · Full text
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Şevin Turcan, Daniel Rohle, Anuj Goenka et al. · Nature · 2012 · 2K citations · Full text
Medicine, Cancer Biology, Oncology +14